ORIGINAL RESEARCH article
Front. Integr. Neurosci.
Volume 19 - 2025 | doi: 10.3389/fnint.2025.1620845
CCL4L2 is a potential biomarker for differentiating central and peripheral vertigo
Provisionally accepted
- 1the Fourth People's Hospital of Lin' an District, Hangzhou, China
- 2Affiliated Hospital of Hangzhou Normal University (Hangzhou Second People's Hospital), Hangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Central vertigo and peripheral vertigo are common clinical conditions with different underlying pathophysiologies. The identification of reliable biomarkers for differential diagnosis remains a challenge.Objective: This study aimed to explore the differential expression of CCL4L2 in the serum of patients with central and peripheral vertigo and assess its diagnostic potential.Methods: A total of 180 patients (90 central vertigo, 90 peripheral vertigo) were enrolled. RNA sequencing was on serum samples to identify differentially expressed genes (DEGs). KEGG pathway enrichment analysis revealed relevant biological pathways. The expression of CCL4L2 was measured using RT-qPCR, and its diagnostic performance was evaluated by Receiver operating characteristic (ROC) curve analysis. The correlation between CCL4L2 expression and biomarkers NSE and S100β was also assessed.Results: RNA sequencing revealed significant differences in gene expression between central vertigo and peripheral vertigo groups. The KEGG pathway analysis identified several enriched pathways, including NF-κB signaling, where CCL4L2 was a key gene. CCL4L2 expression was significantly higher in the CV group compared to the PV group (p < 0.001). ROC analysis demonstrated high diagnostic accuracy for CCL4L2 in distinguishing CV from PV (AUC = 0.909, p < 0.001).Additionally, moderate positive correlations were observed between CCL4L2 and NSE (r = 0.475, p < 0.001), and a weaker correlation with S100β (r = 0.364, p < 0.001).Conclusion: CCL4L2 may serve as a potential biomarker for differentiating central from peripheral vertigo. Its expression is closely associated with inflammatory pathways, making it a promising target for further investigation in vertigo diagnostics.
Keywords: Central vertigo1, peripheral vertigo2, CCL4L23, Biomarker4, ROC curve analysis5
Received: 30 Apr 2025; Accepted: 02 Jul 2025.
Copyright: © 2025 Hong, Wang and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Gaofeng Wang, the Fourth People's Hospital of Lin' an District, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.